These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 20000889)

  • 21. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.
    Zahir H; Greenberg J; Shuster D; Hsu C; Watanabe K; LaCreta F
    Clin Pharmacokinet; 2022 Nov; 61(11):1623-1639. PubMed ID: 36264536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
    Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
    J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PKPD and cardiac single cell modeling of a DDI study with a CYP3A4 substrate and itraconazole to quantify the effects on QT interval duration.
    Jaminion F; Bentley D; Wang K; Wandel C; Derks M; Diack C
    J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):447-459. PubMed ID: 32572738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of drug-drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling.
    Ji T; Chen X; Yeleswaram S
    CPT Pharmacometrics Syst Pharmacol; 2022 Jul; 11(7):894-905. PubMed ID: 35506332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.
    Ohno Y; Hisaka A; Suzuki H
    Clin Pharmacokinet; 2007; 46(8):681-96. PubMed ID: 17655375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
    Perdaems N; Blasco H; Vinson C; Chenel M; Whalley S; Cazade F; Bouzom F
    Clin Pharmacokinet; 2010 Apr; 49(4):239-58. PubMed ID: 20214408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the Pharmacokinetic Drug Interaction of Capmatinib With Itraconazole and Rifampicin and Potential Impact on Renal Transporters in Healthy Subjects.
    Cui X; Chen X; Pognan N; Sengupta T; Rahmanzadeh G; Kornberger R; Giovannini M
    J Clin Pharmacol; 2023 Feb; 63(2):228-238. PubMed ID: 36087217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect.
    Varis T; Kivistö KT; Backman JT; Neuvonen PJ
    Clin Pharmacol Ther; 2000 Nov; 68(5):487-94. PubMed ID: 11103751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first-in-class ACKR3/CXCR7 antagonist, ACT-1004-1239.
    Huynh C; Dingemanse J; Meyer Zu Schwabedissen HE; Fonseca M; Sidharta PN
    Clin Transl Sci; 2024 Jul; 17(7):e13883. PubMed ID: 39010703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study.
    Grönlund J; Saari TI; Hagelberg NM; Neuvonen PJ; Laine K; Olkkola KT
    Clin Drug Investig; 2011; 31(3):143-53. PubMed ID: 21142269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial results.
    Chenel M; Bouzom F; Cazade F; Ogungbenro K; Aarons L; Mentré F
    J Pharmacokinet Pharmacodyn; 2008 Dec; 35(6):661-81. PubMed ID: 19130187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide.
    Niemi M; Tornio A; Pasanen MK; Fredrikson H; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2006 Jun; 62(6):463-72. PubMed ID: 16758263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole.
    Kivistö KT; Lamberg TS; Kantola T; Neuvonen PJ
    Clin Pharmacol Ther; 1997 Sep; 62(3):348-54. PubMed ID: 9333111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
    Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
    Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor.
    Desch M; Wunderlich G; Goettel M; Goetz S; Liesenfeld KH; Chan TS; Rosenbrock H; Sennewald R; Link J; Keller S; Wind S
    Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):91-103. PubMed ID: 34716565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment.
    Watanabe A; Ishizuka T; Yamada M; Igawa Y; Shimizu T; Ishizuka H
    Eur J Clin Pharmacol; 2022 Jan; 78(1):65-73. PubMed ID: 34415382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs.
    Nomoto M; Zamora CA; Schuck E; Boyd P; Chang MK; Aluri J; Siu YA; Lai WG; Yasuda S; Ferry J; Rege B
    Br J Clin Pharmacol; 2018 May; 84(5):952-960. PubMed ID: 29341245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recommendations for the Design of Clinical Drug-Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically-Based Pharmacokinetic Model.
    Chen Y; Cabalu TD; Callegari E; Einolf H; Liu L; Parrott N; Peters SA; Schuck E; Sharma P; Tracey H; Upreti VV; Zheng M; Zhu AZX; Hall SD
    CPT Pharmacometrics Syst Pharmacol; 2019 Sep; 8(9):685-695. PubMed ID: 31215774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Itraconazole or Rifampin on Itacitinib Pharmacokinetics When Administered Orally in Healthy Subjects.
    Barbour AM; Punwani N; Epstein N; Landman R; Cimino E; Yuska B; Wang P; He K; Chen X; Yeleswaram S
    J Clin Pharmacol; 2019 Dec; 59(12):1641-1647. PubMed ID: 31282592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
    Tugnait M; Gupta N; Hanley MJ; Sonnichsen D; Kerstein D; Dorer DJ; Venkatakrishnan K; Narasimhan N
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):214-223. PubMed ID: 31287236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.